David Kittlesen is a notable inventor based in Charlottesville, VA (US). He has made significant contributions to the field of immunology, particularly in the development of peptides that can be utilized in cancer vaccines. With a total of 2 patents, Kittlesen's work is paving the way for advancements in melanoma treatment.

Latest Patents

Kittlesen's latest patents include "Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytotoxic lymphocytes, and uses therefor." This patent identifies melanoma-specific, A1- and A3-restricted CTL epitopes found in tyrosinase and pMel-17, respectively, which may be instrumental in vaccine design. Another significant patent is "Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor." This invention highlights that cysteine-depleted CTL epitopes can elicit a stronger or more specific CTL response compared to their native, cysteine-containing counterparts.

Career Highlights

Kittlesen is affiliated with the University of Virginia Patent Foundation, where he continues to innovate and contribute to research in immunology. His work is crucial in the ongoing fight against melanoma, a type of skin cancer that poses significant health risks.

Collaborations

Some of Kittlesen's notable coworkers include Craig L Slingluff, Jr. and Donald F Hunt. Their collaborative efforts enhance the research and development of effective cancer treatments.

Conclusion

David Kittlesen's innovative work in peptide development is making strides in the field of cancer immunotherapy. His contributions are vital for the advancement of melanoma treatment and vaccine design.